HomeADVM • NASDAQ
add
Adverum Biotechnologies Inc
Previous close
$6.61
Day range
$6.66 - $7.01
Year range
$6.38 - $29.60
Market cap
145.71M USD
Avg Volume
173.16K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 3.78M | -69.64% |
Net income | -18.48M | 41.36% |
Net profit margin | — | — |
Earnings per share | -0.89 | 71.29% |
EBITDA | -19.93M | 36.81% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 173.83M | 22.89% |
Total assets | 253.80M | 5.13% |
Total liabilities | 85.77M | -22.22% |
Total equity | 168.03M | — |
Shares outstanding | 20.80M | — |
Price to book | 0.82 | — |
Return on assets | -20.02% | — |
Return on capital | -20.94% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | -18.48M | 41.36% |
Cash from operations | -19.84M | 14.65% |
Cash from investing | -2.33M | -103.47% |
Cash from financing | -116.00K | -1,550.00% |
Net change in cash | -22.29M | -150.90% |
Free cash flow | -7.13M | 57.79% |
About
Adverum Biotechnologies, Inc., formerly known as Avalanche Biotechnologies, is a publicly traded clinical stage gene therapy company located in Redwood City, California. The company is targeting unmet medical needs for serious ocular and rare diseases, including wet age-related macular degeneration. Wikipedia
Founded
Jan 1, 2006
Headquarters
Website
Employees
121
